US BioTek Laboratories, backed by Pike Street Capital, has merged with NutriPath Pathology, an Australian functional pathology provider. The Shoreline, Washington-based laboratory specializes in advanced immunological and integrative diagnostics, serving integrative medicine practitioners across North America. The merger creates a combined entity with expanded capabilities in functional testing and diagnostics.

Pike Street acquired US BioTek in 2018, positioning the company for strategic growth through acquisitions. The merger with NutriPath Pathology brings together two laboratories sharing a philosophy of providing clinicians with meaningful, actionable data. Both companies focus on serving integrative and functional medicine practitioners with specialized testing services.

NutriPath Pathology will maintain its established brand presence in Australia while operating as part of the combined entity. The merger aims to strengthen support for practitioners through expanded innovation, improved access to testing, and deeper insights. By combining teams and capabilities, the merged organization seeks to enhance its service offerings in the growing functional medicine diagnostics market.